Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma

Pediatric Hematology and Oncology

Volumn 27, Issue 5, 2010, Pages 344-354

  Horinouchi, Masanori ^a   Yagi, Mariko ^b   Imanishi, Hiroyuki ^b   Mori, Takeshi ^b   Yanai, Tomoko ^b   Hayakawa, Akira ^b   Takeshima, Yasuhiro ^b   Hijioka, Michiyo ^b   Okamura, Noboru ^b,d   Sakaeda, Toshiyuki ^c   Matsuo, Masafumi ^b   Okumura, Katsuhiko ^b   Nakamura, Tsutomu ^a,b  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

hepatotoxicity; maintenance chemotherapy; polymorphism; Rho GTPase activating protein 24 (ARHGAP24)

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; KCNIP4 PROTEIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PARD 3B PROTEIN; PROTEIN; RASGRP1 PROTEIN; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN 24; SLC13A1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; LIVER TOXICITY; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MALE; PHARMACOGENETICS; PREDICTION; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS;

EID: 77955102782     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880011003739422     Document Type: Article

References (31)

1. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290:2001-2007.
2. Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol. 2004;125:421-434.
3. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:703-729.
4. Ekhart C, Rodenhuis S, Smits PH, et al. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev. 2009;35:18-31.
5. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151-4157.
6. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30:347-352.
7. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52:166-171.
8. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94:1391-1398.
9. Yang JJ, Cheng C, YangW, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009;301:393-403.
10. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002;100:67-71.
11. Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2002;12:655-658. (Pubitemid 36005675)
12. Bolufer P, Collado M, Barragan E, et al. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007;92:308-314.
13. Katoh M, Katoh M. Identification and characterization of ARHGAP24 and ARHGAP25 genes in silico. Int J Mol Med. 2004;14:333-338.
14. Grise F, Bidaud A, Moreau V. Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta. 2009;1795:137-151.
15. Ohta Y, Hartwig JH, Stossel TP. FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling. Nat Cell Biol. 2006;8:803-814.
16. Shifrin Y, Arora PD, Ohta Y, et al. The role of FilGAP-filamin A interactions in mechanoprotection. Mol Biol Cell. 2009;20:1269-1279.
17. Kobayashi K, Terada C, Tsukamoto I. Methotrexate-induced apoptosis in hepatocytes after partial hepatectomy. Eur J Pharmacol. 2002;438:19-24.
18. Qu HQ, Grant SF, Bradfield JP, et al. Association of RASGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies. J Med Genet. 2009;46:553-554.
19. Mor A, PhilipsMR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol. 2006;24:771-800.
20. Lee SH, Yun S, Lee J, et al. RasGRP1 is required for human NK cell function. J Immunol. 2009;183:7931-7938.
21. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology. 2004;127:1760-1774.
22. Saha B, Nandi D. Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice. Hepatology. 2009;50:1547-1557.
23. Winter-Vann AM, Kamen BA, Bergo MO, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A. 2003;100:6529-6534.
24. Gao L, Macara IG, Joberty G. Multiple splice variants of Par3 and of a novel related gene, Par3L, produce proteins with different binding properties. Gene. 2002;294:99-107.
25. Kohjima M, Noda Y, Takeya R, et al. PAR3β, a novel homologue of the cell polarity protein PAR3, localizes to tight junctions. Biochem Biophys Res Commun. 2002;299:641-646.
26. Valdes AM, Loughlin J, Timms KM, et al. Genome-wide association scan identifies a prostaglandinendoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet. 2008;82:1231-1240.
27. Ikegawa S. New gene associations in osteoarthritis: what do they provide, and where are we going? Curr Opin Rheumatol. 2007;19:429-434.
28. Morohashi Y, Hatano N, Ohya S, et al. Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. J Biol Chem. 2002;277:14965-14975.
29. Lee A, Beck L, Markovich D. The human renal sodium sulfate cotransporter (SLC13A1; hNaSi-1) cDNA and gene: organization, chromosomal localization, and functional characterization. Genomics. 2000;70:354-363.
30. Markovich D, Aronson PS. Specificity and regulation of renal sulfate transporters. Annu Rev Physiol. 2007;69:361-375.
31. Pruunsild P, Timmusk T. Structure, alternative splicing, and expression of the human and mouse KCNIP gene family. Genomics. 2005;86:581-593.